[Effectiveness of piperacillin in the antibacterial treatment of intra-abdominal infections in children]. 1986

M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel

The effectiveness of piperacillin was investigated in 30 children operated upon for peritonitis: 13 had acute appendicitis with puriform peritoneal reaction, or a recently perforated appendix; 5 had generalized peritonitis of appendicular origin, and 13 had intraperitoneal abscess. In the 12 children who underwent right iliac appendicectomy (with post-operative drainage in 3), piperacillin was administered alone during 5 days; clinical and bacteriological cure was obtained in all cases; the mean duration of stay in hospital was 7 days. The 5 cases of generalized peritonitis required drainage; piperacillin was given alone in 4 of them and combined with an aminoglycoside and metronidazole in one who was in poor general condition. Bacteriology showed a predominance of Escherichia coli alone or associated with other organisms. Clinical and bacteriological cure was obtained in 3 patients; the mean duration of stay in hospital was 12 days. Seven of the 13 cases of intraperitoneal abscess needed drainage. Piperacillin was administered alone for 7 days on average in 10 cases and combined with an aminoglycoside and metronidazole in 2 cases. Eight patients had a favourable course, 5 developed complications. In all 3 groups piperacillin was tell tolerated. A patch of urticaria was noted in 2 cases and a transient skin rash in 2 other cases. No neutropenia was observed in these children whose treatment never exceeded 10 days.

UI MeSH Term Description Entries
D008297 Male Males
D010532 Peritoneal Diseases Pathological processes involving the PERITONEUM. Peritoneal Disease
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D010878 Piperacillin Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics. AB-Piperacillin,Cl-227193,Pipcil,Pipera-Hameln,Piperacillin Curasan,Piperacillin Fresenius,Piperacillin Hexal,Piperacillin Monosodium Salt,Piperacillin Sodium,Piperacillin-Ratiopharm,Pipercillin,Pipracil,Pipril,T-1220,T1220,AB Piperacillin,Cl 227193,Cl227193,Curasan, Piperacillin,Monosodium Salt, Piperacillin,Pipera Hameln,Piperacillin Ratiopharm,Salt, Piperacillin Monosodium,Sodium, Piperacillin,T 1220
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000038 Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection. Abscesses

Related Publications

M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel
January 1995, Acta chirurgica Belgica,
M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel
January 1994, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement,
M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel
March 1993, Surgery, gynecology & obstetrics,
M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel
July 1994, Intensive care medicine,
M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel
December 1992, Antimicrobial agents and chemotherapy,
M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel
September 1999, The European journal of surgery = Acta chirurgica,
M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel
January 1984, Clinical therapeutics,
M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel
July 1989, Journal of chemotherapy (Florence, Italy),
M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel
September 2001, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
M Vergnaud, and P Ravasse, and N Eustratiades, and B Malbruny, and M C Laschon, and J Laurent, and C Morel
January 1994, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement,
Copied contents to your clipboard!